Thursday, March 12, 2026 8:58:29 PM
Since you didn’t respond, I asked ChatGPT. The explanation is below. I don’t suspect any major issues—just trying to understand the process. Please let me know your opinion on why we might not fall under this category.
1️⃣ Within 28 days the company must respond
After receiving the negative or provisional opinion, the company must tell MHRA/CHM within 28 days whether it plans to:
submit written responses
request an oral hearing
or withdraw the application
If the company says “we will respond but need several months to prepare data,” that is recorded by MHRA.
2️⃣ The review clock pauses
Once the company indicates it will respond:
the regulatory clock stops
the application is paused
The company can then take several months (often up to ~6 months) to prepare its response.
3️⃣ CHM normally waits for the full response
During those months:
CHM does not usually re-review the case
it is not typically discussed again at monthly meetings
The committee generally waits until the company submits the full response package.
4️⃣ After the company submits the response
When the response arrives:
MHRA scientists review the new data
The case is scheduled for a future CHM meeting
CHM discusses the new evidence and gives updated advice to MHRA
1️⃣ Within 28 days the company must respond
After receiving the negative or provisional opinion, the company must tell MHRA/CHM within 28 days whether it plans to:
submit written responses
request an oral hearing
or withdraw the application
If the company says “we will respond but need several months to prepare data,” that is recorded by MHRA.
2️⃣ The review clock pauses
Once the company indicates it will respond:
the regulatory clock stops
the application is paused
The company can then take several months (often up to ~6 months) to prepare its response.
3️⃣ CHM normally waits for the full response
During those months:
CHM does not usually re-review the case
it is not typically discussed again at monthly meetings
The committee generally waits until the company submits the full response package.
4️⃣ After the company submits the response
When the response arrives:
MHRA scientists review the new data
The case is scheduled for a future CHM meeting
CHM discusses the new evidence and gives updated advice to MHRA
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
